Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above

NCT01640314 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
126
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Novartis Vaccines